Raytheon awarded $71 million in Navy contracts for missile systems
Investing.com - Oppenheimer has reiterated an Outperform rating and $205.00 price target on Biogen (NASDAQ:BIIB), a prominent biotechnology company currently trading below its InvestingPro Fair Value, following the company’s second-quarter financial results. With a market capitalization of $18.7 billion and a P/E ratio of 12.5, the stock shows promising valuation metrics.
Biogen reported second-quarter revenue of $2.65 billion, exceeding Oppenheimer’s estimate of $2.29 billion and the consensus estimate of $2.32 billion. The company’s trailing twelve-month revenue stands at $9.8 billion, with an impressive gross margin of 76%. The company has increased its fiscal year 2025 guidance, now projecting flat revenues at constant currency compared to fiscal year 2024.
In the multiple sclerosis segment, Biogen’s U.S. sales reached $657 million, driven by Vumerity demand and GTN dynamics, which partially offset international weakness resulting from generic pressure. The rare disease portfolio is viewed as a future growth driver, with stable Spinraza demand and positive trends for the Skyclarys launch.
Oppenheimer expressed optimism about longer-term growth prospects from Leqembi, particularly as European Union approval and upcoming milestones are expected to expand uptake. Biogen also highlighted pipeline progress, including indication expansion for felzartamab and progression of next-generation salanersen into registrational trials.
The research firm noted encouragement by Biogen’s continued interest in research-driven business development, following the success of partnered and acquired programs. With analyst targets ranging from $115 to $260 and a consensus recommendation of 2.25, the stock presents interesting opportunities. Discover more insights and 8 additional ProTips about Biogen in its comprehensive InvestingPro Research Report, part of our coverage of 1,400+ US stocks.
In other recent news, Biogen Inc. reported robust financial results for the second quarter of 2025, significantly surpassing earnings expectations. The company’s earnings per share (EPS) reached $5.47, exceeding the projected $3.99 by 37.09%. Additionally, Biogen’s revenue was $2.6 billion, outperforming the anticipated $2.32 billion, resulting in a 12.07% surprise. These results highlight Biogen’s strong performance in the recent quarter. The company’s financial success was a key development for investors. The earnings beat reflects positively on Biogen’s operational efficiency and market strategy. This performance comes amidst a competitive landscape in the pharmaceutical industry. Such financial achievements are crucial for investor confidence and future outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.